Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics

PURPOSE: Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; however, tools to quantify in situ drug exposure are few. We have...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishra, Akhilesh, Kumar, Dhiraj, Gupta, Kuldeep, Lofland, Gabriela, Sharma, Ajay Kumar, Banka, Dhanush S., Hobbs, Robert F., Dannals, Robert F., Rowe, Steven P., Gabrielson, Edward, Nimmagadda, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890130/
https://www.ncbi.nlm.nih.gov/pubmed/36449662
http://dx.doi.org/10.1158/1078-0432.CCR-22-1931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890130/
https://www.ncbi.nlm.nih.gov/pubmed/36449662
http://dx.doi.org/10.1158/1078-0432.CCR-22-1931

Ejemplares similares